Actively Recruiting
Safety and Efficacy Study of ALN-2232 Alone or With Tirzepatide in Adults With Obesity
Led by Alnylam Pharmaceuticals · Updated on 2026-10-13
156
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, effectiveness, pharmacokinetics, and pharmacodynamics of ALN-2232 in adults with obesity. The study evaluates single ascending doses, multiple doses of ALN-2232 alone, and multiple doses of ALN-2232 combined with tirzepatide. This research aims to better understand how these treatments work and their effects on patients with obesity. Participants will be randomly assigned to receive either a single dose or multiple doses of ALN-2232 or placebo. Some will also receive tirzepatide once weekly alongside ALN-2232. All doses are given as injections under the skin. The study includes separate parts for each dosing regimen to assess safety and body weight changes over time. During the study, participants will have regular visits to monitor safety, body weight, and drug levels in their blood and urine. Researchers will measure adverse events up to 12 months and track changes in body weight and body composition up to 6 to 12 months. Laboratory tests and protein analyses in fat tissue will also be performed to understand treatment effects. The total participation duration may last up to one year.
CONDITIONS
Brief Title
A Study to Evaluate ALN-2232 in Participants With Obesity
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here